

**Eric Krasnoff**  
Chairman &  
Chief Executive Officer  
November 12, 2008



## Forward-Looking Statements

The matters discussed in this presentation contain “forward-looking statements” as defined in the Private Securities Litigation reform Act of 1995. Forward-looking statements are based on current Company expectations and are subject to risks and uncertainties, which could cause actual results to differ materially. Statements about future performance, earnings projections, earnings guidance, management’s expectations about its future cash needs and effective tax rate, and other future events or developments are forward-looking statements. Forward-looking statements are those that use terms such as “anticipate”, “should”, “believe”, “estimate”, “expect”, “intend”, “plan”, “predict”, “potential”, or similar expressions about matters that are not historical facts. Such risks and uncertainties include those discussed in our Annual Report on Form 10-K and other reports the Company files with the Securities and Exchange Commission, including, among others, the impact of the current economic environment, including the current credit market crisis, volatility in currency and energy costs and other macro-economic challenges currently affecting the Company, our customers and vendors and the economy of the United States and other parts of the world.

Management uses certain non-GAAP measurements to assess the Company’s current and future financial performance. The non-GAAP measurements do not replace the presentation of Pall’s GAAP financial results. These measurements provide supplemental information to assist management in analyzing the Company’s financial position and results of operations. The Company has chosen to provide this information to facilitate meaningful comparisons of past, present and future operating results and as a means to emphasize the results of ongoing operations. Reconciliations of the non-GAAP financial measures used in this presentation to the most directly comparable GAAP measures appear on the last slide of this presentation (in the Reconciliation Appendix) and are also available on Pall’s website at [www.pall.com/investor](http://www.pall.com/investor).

## We Are Fluid Management Specialists

- Providing enabling and process-enhancing filtration, separation and purification technologies for diverse markets, applications and geographies
- No competitor overlaps in more than 20% of our business
- #1 or #2 in our major markets
- 75% of revenues are consumables
- Founded in 1948



***Our Vision : One day all fluids will pass through Pall products***

## Strong Planning and Robust Execution

The bedrock of our plan supports the expectation to outperform in the filtration space and strengthen the company's position to achieve

*Sustainable, Profitable  
Growth*



# A Track Record Of Performance

## 2004 5-Year Plan Update

	Original 2004 Plan Goals (Updated in 2006)		2008 Actuals		
	%	\$'000's		%	\$'000's
Sales	6.0% - 8.5%*	\$2,380	\$2,541	7.2%	\$2,572
Gross Profit	49.0% - 50.0%	\$1,166	\$1,270	47.1%	\$1,211
SG&A	30.5% - 30.0%	\$726	\$762	29.1%	\$750
R&D	Approx 3%	\$71	\$71	2.8%	\$72
Pro forma EBIT***	15.5% - 17.2%	\$369	\$437	15.2%	\$390
Interest	1% or less	\$24	\$12	1.3%	\$33
ROTC					\$32
Income Taxes	23.0% - 22.0%**	\$79	\$94	33.2%	\$108
Net Earnings	11.2% - 13.1%	\$266	\$332	8.4%	\$217
Pro forma Net Earnings***	11.2% - 13.1%	\$266	\$332	9.5%	\$244
Pro forma EPS – Diluted***		\$2.14	\$2.68		\$1.97

\* CAGR for FY2007/09

\*\* Effective Tax Rate

\*\*\* Excluding Restructuring and Other Charges



***Energy & Water Needs***  
***Environmentalism***  
***Emerging Pathogens***  
***Customer Innovation***  
***Regulatory Requirements***

## Pall Industrial \$27 Billion Market

## Pall Life Sciences \$8 Billion Market



### Energy, Water & Process Technologies

- Water Processing
- Energy
  - Fuels & Chemicals
  - Power Generation
- Food & Beverage
- Industrial Manufacturing

### Aerospace & Transportation

- Commercial
- Military
- OEM

### Microelectronics

- Semiconductor
- Consumer Electronics

### BioPharmaceuticals

- Biologics (Vaccines)
- Biotechnology Drugs
- Classic Pharmaceuticals
- Validation Services
- Diagnostics

### Medical


- Hospital & Blood Banking Products
- BioSciences
  - Cell Therapy
  - OEM Materials
  - Laboratory Tools
  - Genomics/Proteomics

*Two separate, integrated businesses each with its own global manufacturing, R&D, sales, marketing and technical support*

Provide real customer benefits in performance and efficiency



Leverage capabilities and experiences to further differentiate Pall



## *Total Fluid Management*

Place Pall systems and products at the heart of a customer's processes



Raise the level of engagement to senior decision makers





## Selling systems enables Pall to:

- Apply our process expertise to provide the optimal separation solution
- Leverage system platforms across multiple diverse applications
- Expand our TFM capabilities
  - Add new customers and enter new markets
  - Develop greater customer intimacy and loyalty
- Provide high value proposition, cost effective solutions to our customers
- Grow our highly profitable annuity stream



**Pall's Euroflow® chromatography columns enable pharmaceutical companies to produce safe drugs cost-effectively**


# Geographic Diversity



**Total Sales:**  
\$2.6 Billion


## 2008 Sales by Geography

(amounts in millions)



## 2008 Sales by Market

(amounts in millions)



## MANUFACTURING INITIATIVES

- Facilities/  
Infrastructure  
Rationalization
- Lean Manufacturing
- Supply Chain
- Logistics

# *Continuous Improvement Initiatives*

## INFRASTRUCTURE INITIATIVES

- Centers of  
Excellence
- Global Best  
Practices
- Streamlining  
Process

## CORPORATE INITIATIVES

- Ethics & Compliance
- Pricing Excellence
- ERM
- Systems Margin Improvement
- Establish Swiss Entity

### Major Global Drivers:

- Drinking Water Regulation
- More Stringent Waste Water Regulation and Specification
- Increased Need For Desalination
- Limited Fresh Water Supply
- Pathogens in Water Supply

**Pall Aria™  
Water Treatment System**





### Major Global Drivers:

- Shift to Alternative Fuel & Power Generation Sources
- Increasing Demand for Chemicals, Minerals, Fuels & Power
- Increasing Demand on Industrial Producers to Control Emissions



**Pall Blowback Filter System  
used to remove flue gas  
emissions in refineries**



## Major Global Drivers:


- Consumer Electronics
  - Displays
  - Personal Video
  - Game Consoles
  - Climate Control/Energy Production
  - Telephone, E-Mail, Television
  - Personal Storage
- Industrial
  - Solar Cells
  - Navigation Systems
  - Satellite Radio
  - Impact Sensors
  - High speed, high resolution printing
- Healthcare
  - Diagnostics
  - Telemonitoring/sensors



**Pall fully-automated, Dynamic Membrane Filtration System, recovers ~95% of DI water used during solar silicon ingot shaping**

## Major Global Drivers:

- Asset Protection
  - Lowering Cost of Ownership
  - Extending Useful Life
  - Extending Operational Capabilities
- Environmental Protection
- Homeland Security



**Air Cleaners**



**Fluid Purifiers**



**Water Treatment Systems**



**Exhaust Filters**



## Major Global Drivers:

- Blood/Transfusion
  - Life Saving Therapy
  - Safety
  - Rising Level of Health Care Requirements
- Cell Therapy
  - Hope of Stem Cells to Provide New Treatments
- Hospital
  - Litigation Costs and Lack of Reimbursement for Healthcare Associated Infections (HAIs)



**Leukotrap® Blood Systems**



**Pall Cell Therapy Systems**




**Pall Aquasafe™ Filters**





## Major Global Drivers:


- Biotechnology & Vaccines
  - Strong Pipeline of Monoclonal Antibodies & Recombinants
  - Increase in Generics & BioSimilarars Especially in Asia
  - Contract Manufacturing & New Plant Builds
  - Importance of Process Validation & Time to Market



The acquisition of GeneSystems, with its patented approach to rapid microbiological detection equipment and disposables, expands Pall's Total Fluid Management<sup>SM</sup> (TFM) capabilities in the \$1 billion biopharmaceuticals process monitoring market

**Lisa McDermott**  
CFO & Treasurer  
November 12, 2008






- (1) LC Organic
- (2) LC mid-point of 2009 range of 4.0-6.5% growth.
- (3) LC 8.75% mid-point of organic 2010-2013 4-year CAGR based on 2009-2013 mid-point CAGR of 8.0%.

## Cycle To Cycle Comparison


### How is Pall different today than the last down cycle?

- Greater strategic international diversification
- Investment in emerging economies



### How is Pall different today than the last down cycle?


- TFM strategy a resounding success with >3X installed base of systems solidifying long-term customer relationships
- Increase in installed base provides customer assurance of experience and success
- Growing standardization reduces ongoing costs



## Cycle To Cycle Comparison

How is Pall different today than the last down cycle?


**Permanently Reduced Our Cost Structure**



\* Projected

## How is Pall different today than the last down cycle?

### Net Debt/Capital



Strong Cash Generation Has Been Used To:

- **Strengthen the Balance Sheet**, while also...
- Providing steadily increasing cash returns to Shareholders

**Total Cash Returned to Shareholders Over the Period  
Approximately \$840 Million\***

\*Includes Share Repurchases

## FY09 Guidance as the Starting Point

	FY08 Actuals		FY2009 Guidance Range		
	\$'000's	%	%	\$'000's	
<b>Sales</b>	\$2,572		4.0%-6.5% LC	\$2,675	\$2,740
<b>Gross Profit</b>	\$1,211	47.1%	Approx 48.0%	\$1,285	\$1,335
<b>Pro forma EBIT <sup>(1)</sup></b>	\$390	15.2%	15.0%-16.5%	\$400	\$455
<b>Interest</b>	\$33	1.3%	Approx 1.5%	\$45	\$40
<b>Income Taxes</b>	\$108	33.2%	Approx 30%-33% <sup>(2)</sup>	\$120	\$130
<b>Net Earnings</b>	\$217	8.4%	9.0%-9.5%	\$240	\$265
<b>Pro forma Net Earnings <sup>(1)</sup></b>	\$244	9.5%	9.5%-10.0%	\$250	\$275
<b>Pro forma EPS – Diluted <sup>(1)</sup></b>	\$1.97		Local Currency	\$2.10	\$2.30
			18¢ Impact of Translation	\$1.92	\$2.12

(1) Excludes Restructuring and Other Charges

(2) Effective Tax Rate



*(Provided at Pall Investor Day 10/29/08)*

	FY08 Actuals		FY2013 Outlook <sup>(4)</sup>		
	\$'000's	%	%	\$'000's	
Sales	\$2,572		7.0%-9.0% <sup>(1)</sup>	\$3,630	\$3,980
Gross Profit	\$1,211	47.1%	49.0%-51.0%	\$1,785	\$2,025
SG&A	\$750	29.1%	27.5%-26.5%	\$1,005	\$1,045
R&D	\$72	2.8%	Approx 3.0%-3.5%	\$115	\$130
Pro forma EBIT <sup>(3)</sup>	\$390	15.2%	18.5%-21.0%	\$665	\$850
Income Taxes	\$108	33.2%	25.0%-27.0% <sup>(2)</sup>	\$175	\$210
Net Earnings	\$217	8.4%	13.0%-16.0%	\$480	\$635
Pro forma Net Earnings <sup>(3)</sup>	\$244	9.5%		\$480	\$635
Pro forma EPS – Diluted <sup>(3)</sup>	\$1.97			\$4.25	\$5.60

(1) LC 5-year sales CAGR

(2) Effective Tax Rate

(3) Excludes Restructuring and Other Charges

(4) FX Neutral to '08 Rates



**FY2013 at Midpoint** *(Provided at Pall Investor Day 10/29/08)*

- Sales of about \$3.8 billion – A five-year CAGR of 8.0% versus 6.5% during the five years ended FY08
- EBIT<sup>(1)</sup> of \$755 million and 20% versus 15.2% in FY08
- Effective tax rate of 25% – 27%
- Net Earnings<sup>(1)</sup> of \$555 million and >14.5% versus 8.4% in FY08
- ROE of over 25.5% versus 19.7% in FY08
- Operating Cash Flow of over \$600 million

**FY13 Midpoint EPS of \$4.92 versus \$1.97<sup>(2)</sup> in FY08**

(1) Excludes Restructuring and Other Charges

(2) Pro forma

(3) FX Neutral to '08 Rates

**PALL** Pall Corporation



ENABLING A  
GREENER  
FUTURE



## Appendix: Reconciliation of As Reported to Pro Forma EPS, Earnings and EBIT

<i>Full Year</i>	<b>FY 2008</b>	<i>Full Year</i>	<b>FY 2008</b>
Diluted EPS as reported	\$ 1.76	Net earnings as reported	\$ 217.3
ROTC and one-time purchase accounting adjustment, after pro forma tax effect	0.17	ROTC and one-time purchase accounting adjustment, after pro forma tax effect	21.4
Tax adjustments	<u>0.04</u>	Tax adjustments	<u>4.9</u>
Pro forma diluted EPS	<u>\$ 1.97</u>	Pro forma earnings	<u>\$ 243.6</u>

<b>Operating Profit (in millions)</b>	<b>FY 2008</b>
Life Sciences operating profit	\$ 197.8
Industrial operating profit	<u>\$ 245.8</u>
Total operating profit	\$ 443.6
General corporate expenses	<u>\$ (54.0)</u>
Earnings before ROTC, interest & income taxes	\$ 389.6
ROTC	<u>\$ (31.5)</u>
Earnings before interest & income taxes	<u>\$ 358.1</u>